Ligand Pharmaceuticals Incorporated Stock News

Positive remdesivir news 'bodes well' for BioCryst, says JMP Securities JMP Securities BCRX GILD

NYSE market internals summary $NYE

Roots Analysis has announced the addition of the "Fragment-based Drug Discovery Market: Library and Service Providers, 2020-2030" report to its list of offerings.

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced tha

Ligand Pharmaceuticals Inc. (NASDAQ:LGND)’s share price traded up 5.1% on Friday . The stock traded as high as $98.11 and last traded at $97.63, 240,600 shares changed hands during mid-day trading.

As a general rule, we think profitable companies are less risky than companies that lose money. Having said that...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today tha

Congress Asset Management Co. MA increased its stake in shares of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) by 58.8% in the first quarter, according to its most recent 13F filing with the Securities a

Perrigo (NYSE:PRGO) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) provided today details of its plans to report first quarter 2020 financial results on May 6, 2020. Ligand’s CEO John Higgins, President and COO Mat

Ligand Pharmaceuticals (NASDAQ:LGND) was upgraded by investment analysts at BidaskClub from a “hold” rating to a “buy” rating in a note issued to investors on Wednesday, BidAskClub reports. LG

Ligand Pharmaceuticals (NASDAQ:LGND) and ASTELLAS PHARMA/ADR (OTCMKTS:ALPMY) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of

Louisiana State Employees Retirement System decreased its holdings in shares of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) by 4.8% in the 1st quarter, according to the company in its most recent Form 1